A CASE OF ACTIVE ACROMEGALIA COMPLICATED KIDNEY CANCER WITH ADNASTAL METASTASIS

Authors

  • Mikityuk M. R. SI «V. Danilevsky Institute of Endocrine Pathology Problems of AMS of Ukraine», Kharkiv, Ukraine; Kharkiv Medical Academy of Postgraduate Education https://orcid.org/0000-0002-6169-7628
  • Khizhnyak O. O. SI «V. Danilevsky Institute of Endocrine Pathology Problems of AMS of Ukraine», Kharkiv, Ukraine; Kharkiv Medical Academy of Postgraduate Education https://orcid.org/0000-0002-4541-5248
  • Tyazhelova O. V. SI «V. Danilevsky Institute of Endocrine Pathology Problems of AMS of Ukraine», Kharkiv, Ukraine
  • Alekseeva I. І. SI «V. Danilevsky Institute of Endocrine Pathology Problems of AMS of Ukraine», Kharkiv, Ukraine
  • Kravchenko G. G. SI «V. Danilevsky Institute of Endocrine Pathology Problems of AMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2010.2.09

Keywords:

Insulin-like growth factor-1

Abstract

Insulin-like growth factor-1 (IRF-1) plays an important role in the development of malignant neoplasms such as colorectal cancer, breast and lung cancer. Several clinical and experimental studies have demonstrated the effect of high levels of IRF-1 in the blood and the expression of its receptors in tissues on their malignancy. Somatotropic hormone of the pituitary gland (STH) is involved in oncogenesis not only indirectly, by increasing the production of IRF-1 by the liver, but also directly but, realizing its effects through STG receptors (rSTG), are expressed in various tumors

References

A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women [Text] / E. Giovannucci, M. N. Pollak, E. A. Platz [et al.] / Cancer Epidemiol. Biomarkers Prev. — 2000. — № 9. — Р. 345–349.

Circulating concentrations of insulin-like growth factor-I and risk of breast cancer [Text] / S. E. Hankinson, W. C. Willett, G. A. Colditz [et al.] / Lancet. — 1998. — Vol. 351. — P. 1393–1396.

Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis [Text] / H. Yu, M. R. Spitz, Mistry [et al.] / J. Natl. Cancer. Inst. — 1999. — Vol. 91. — P. 151–156.

The insulin-like growth factor type 1 receptor and colorectal neoplasia: insights into invasion [Text] / A. S. Allison, M. A. McIntyre, C. McArdle, F. K. Habib / Hum. Pathol. — 2007. — Vol. 38. — P. 1590–1602.

Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas [Text] / A. Ouban, P. Muraca, T. Yeatman, D. Coppola / Hum. Pathol. — 2003. — Vol. 34. — P. 803–808.

The oncogenic potential of growth hormone [Text] / J. K. Perry, B. S. Emerald, H. C. Mertani, P. E. Lobie / Growth Horm. IGF. Res. — 2006. — Vol. 16. — P. 277–289.

Growth hormone receptor expression is up-regulated during tumorigenesis of human colorectal cancer [Text] / X. Wu, F. Liu, X. Yao [et al.] / J. Surg. Res. — 2007. — Vol. 143. — P. 294–299.

Growth hormone receptor is expressed in human breast cancer [Text] / M. Gebre-Medhin, L. G. Kindblom, H. Wennbo [et al.] / J. Pathol. — 2001. — Vol. 158. — P. 1217–1222.

Ben-Shlomo A. Acromegaly [Text] / A. Ben-Shlomo, S. Melmed // Endocrinol. Metabol. Clin. North. Am. — 2008. — Vol. 37, № 1. — P. 101–122.

Loeper S. Acromegaly: re-thinking the cancer risk [Text] / S. Loeper, S. Ezzat // Rev. Endocr. Metabol. Disord. — 2008. — № 9. — Р. 41–58.

Jenkins P. J. Cancers associated with acromegaly [Text] / P. J. Jenkins // Neuroendocrinology. — 2006. — Vol. 83. — P. 218–223.

The prevalence of benign and malignant tumors in patients with acromegaly at a single institute [Text] / M. Kurimoto, I. Fukuda, N. Hizuka, K. Takano / Endocrinol. J. — 2008. — Vol. 55. — P. 67–71.

Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA) [Text] / A. Mestron, S. M. Webb, R. Astorga [et al.] / Europ. J. Endocrinol. — 2004. — Vol. 151. — P. 439–446.

Criteria for Cure of Acromegaly: A Consensus Statement [Text] / A. Giustina, A. Barkan, F. F. Casanueva, F. Cavagnini // J. Clin. Endocrinol. Metabol. — 2000. — Vol. 85, № 2. — P. 526–529.

Марова Е. И. Нейроэндокринология [Teкст] / Е. И. Марова. — Ярославль: [б. и.], 1999. — 506 с. 16. Handbook of Acromegaly [Text] / ed. J. Wass . — [S. I.] BioSсientifica, 2004. — 97 p.

Guidelines for Acromegaly Management: An Update [Text] / S. Melmed, A. Colao, A. Barkan, M. Molitch [et al.] / J. Clin. Endocrinol. Metabol. — 2009. — Vol. 94, № 5. — Р. 1509–1517.

Караченцев Ю. И. Акромегалия и гиган- тизм [Teкст] / Ю. И. Караченцев, О. О. Хижняк, М. Р. Микитюк. — Старт Полиграф: Киев, 2009. — 128 с.

Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue Octreotide [Text] / A. Colao, P. Marzullo, A. Cuocolo [et al.] / Clin. Endocrinol. (Oxf). — 2003. — № 58. — Р. 169–176.

Multicenter Italian Study Group on Lanreotide. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced growth hormone and insulin-like growth factor-I decrease in acromegaly: a prospective multicenter study [Text] / G. Lombardi, A. Colao, P. Marzullo [et al.] / J. Endocrinol. Invest. — 2006. — № 25. — Р. 971–976.

Cardiovascular consequences of early-onset growth hormone excess [Text] / A. Colao, L. Spinelli, A. Cuocolo [et al.] / J. Clin. Endocrinol. Metabol. — 2002. — № 87. — Р. 3097–3104.

Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group [Text] / S. M. Orme, R. J. McNally, R. A. Cartwright, P. E. Belchetz // J. Clin. Endocrinol. Metabol. — 1998. — Vol. 83. — P. 2730–2734.

Шпарик Я. В. Рак нирки: останнi досягнення медикаментозного лiкування [Teкст] / Я. В. Шпарик // Онкология. — 2008. — Т. 10, № 4. — С. 436–442.

Downloads

Published

2010-06-09

How to Cite

Mikityuk, M., Khizhnyak, O., Tyazhelova, O. V., Alekseeva I. І., & Kravchenko, G. G. (2010). A CASE OF ACTIVE ACROMEGALIA COMPLICATED KIDNEY CANCER WITH ADNASTAL METASTASIS. Problems of Endocrine Pathology, 32(2), 59-65. https://doi.org/10.21856/j-PEP.2010.2.09

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.